Pembrolizumab (MK-3475) and Epacadostat (INCB024360) in Thymic Carcinomas
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2017
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- 26 Oct 2017 Protocol amended with addition of Epacadostat and time frame of secondary endpoint revised.
- 26 Oct 2017 Planned number of patients changed from 17 to 67.
- 26 Oct 2017 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.